A share price of TG Therapeutics Inc [TGTX] is currently trading at $35.57, up 1.72%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TGTX shares have gain 11.19% over the last week, with a monthly amount glided 20.80%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, TD Cowen started tracking the stock with Buy rating on October 29, 2024, and set its price target to $50. On August 02, 2023, upgrade upgraded it’s rating to Neutral and revised its price target to $12 on the stock. BofA Securities initiated its recommendation with a Underperform and recommended $5 as its price target on May 20, 2022. B. Riley Securities reiterated a Buy rating for this stock on February 23, 2022, and downed its price target to $35. In a note dated November 15, 2021, Goldman downgraded an Sell rating on this stock and revised its target price from $33 to $26.
TG Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $21.16 and $46.48. Currently, Wall Street analysts expect the stock to reach $19.8 within the next 12 months. TG Therapeutics Inc [NASDAQ: TGTX] shares were valued at $35.57 at the most recent close of the market. An investor can expect a potential drop of -44.34% based on the average TGTX price forecast.
Analyzing the TGTX fundamentals
Trailing Twelve Months sales for TG Therapeutics Inc [NASDAQ:TGTX] were 454.07M which represents 92.13% growth. Gross Profit Margin for this corporation currently stands at 0.87% with Operating Profit Margin at 0.19%, Pretax Profit Margin comes in at 0.15%, and Net Profit Margin reading is 0.13%. To continue investigating profitability, this company’s Return on Assets is posted at 0.09, Equity is 0.29 and Total Capital is 0.17. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 34.86 points at the first support level, and at 34.16 for the second support level. However, for the 1st resistance point, the stock is sitting at 36.18, and for the 2nd resistance point, it is at 36.79.
Ratios To Look Out For
To put it in perspective, the Current Ratio for TG Therapeutics Inc [NASDAQ:TGTX] is 3.86. Also, the Quick Ratio is 2.96, while the Cash Ratio stands at 0.82. Considering the valuation of this stock, the price to sales ratio is 12.43, the price to book ratio is 20.33 and price to earnings (TTM) ratio is 95.06.
Transactions by insiders
Recent insider trading involved Lonial Sagar, Director, that happened on Sep 11 ’25 when 20852.0 shares were sold. Director, Lonial Sagar completed a deal on Sep 11 ’25 to buy 20852.0 shares. Meanwhile, Director Echelard Yann sold 10000.0 shares on Jun 13 ’25.